Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that ...
In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...
What are bankers and analysts saying about concerns that an AI bubble could negatively impact credit markets? Read more here.
NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...
Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results